Literature DB >> 16608376

Drug dosage in the elderly: dermatological drugs.

Anna Flammiger1, Howard Maibach.   

Abstract

Drug pharmacokinetics and pharmacodynamics may be altered in the elderly. An important contribution is made by decreased renal function, but biotransformation in the liver may also play a role. Commonly prescribed dermatological drugs such as methotrexate and cetirizine are likely to be eliminated more slowly in the elderly and potentially hepatotoxic drugs such as itraconazole and acitretin should be used with caution. Altered drug distribution as a result of body composition changes can lead to prolonged half-life or higher plasma concentrations of many drugs. Higher prevalence of adverse drug reactions and multidrug regimens, and large interindividual variability in drug response make drug dosage and administration in the elderly challenging. New immunobiological agents such as alefacept, efalizumab and etanercept, which are approved for treatment of psoriasis, seem to be as well tolerated in the elderly as in younger patients. A recommended approach when prescribing drugs to the elderly would be to start with a small initial dose and to reduce the number of drugs administered simultaneously. It is crucial to simplify the drug regimen as much as possible in order to enhance drug management in the elderly. To improve pharmacotherapy in the elderly, we review age-related changes in pharmacokinetics that are likely to play a role in dermatological practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16608376     DOI: 10.2165/00002512-200623030-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  104 in total

1.  Assessment of adherence to renal dosing guidelines in long-term care facilities.

Authors:  A Papaioannou; J A Clarke; G Campbell; M Bédard
Journal:  J Am Geriatr Soc       Date:  2000-11       Impact factor: 5.562

2.  Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver.

Authors:  T P Almdal; T I Sørensen
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

Review 3.  An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.

Authors:  Amita Joshi; Robert Bauer; Peter Kuebler; Mark White; Cecelia Leddy; Peter Compton; Marvin Garovoy; Paul Kwon; Patricia Walicke; Russell Dedrick
Journal:  J Clin Pharmacol       Date:  2006-01       Impact factor: 3.126

Review 4.  Alefacept: a safety profile.

Authors:  Noah Scheinfeld
Journal:  Expert Opin Drug Saf       Date:  2005-11       Impact factor: 4.250

5.  Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.

Authors:  Alice B Gottlieb; Craig L Leonardi; Bernard S Goffe; Jean-Paul Ortonne; Peter C M van der Kerkhof; Ralph Zitnik; Arline Nakanishi; Angelika Jahreis
Journal:  J Am Acad Dermatol       Date:  2006-03       Impact factor: 11.527

6.  Hepatotoxicity associated with itraconazole.

Authors:  S Gallardo-Quesada; J Luelmo-Aguilar; C Guanyabens-Calvet
Journal:  Int J Dermatol       Date:  1995-08       Impact factor: 2.736

7.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

Review 8.  Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.

Authors:  Gil Yosipovitch; Mark B Y Tang
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

9.  Socio-demographic factors related to the prevalence of adverse drug reaction at hospital admission in an elderly population.

Authors:  Francisco Caamaño; Claudio Pedone; Guiseppe Zuccalà; Pierugo Carbonin
Journal:  Arch Gerontol Geriatr       Date:  2005 Jan-Feb       Impact factor: 3.250

Review 10.  Age-related changes in liver structure and function: Implications for disease ?

Authors:  Douglas L Schmucker
Journal:  Exp Gerontol       Date:  2005 Aug-Sep       Impact factor: 4.032

View more
  6 in total

Review 1.  Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly.

Authors:  Ayman M Noreddin; Virginia Haynes
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

2.  Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly.

Authors:  Erminia Ridolo; P Kihlgren; I Pellicelli; M C Nizi; F Pucciarini; C Incorvaia
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 3.  Managing moderate-to-severe psoriasis in the elderly.

Authors:  Nicola Balato; Cataldo Patruno; Maddalena Napolitano; Angela Patrì; Fabio Ayala; Raffaele Scarpa
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

Review 4.  Mycoses in the elderly.

Authors:  H Hof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-13       Impact factor: 3.267

5.  Allergic diseases in the elderly.

Authors:  Victoria Cardona; Mar Guilarte; Olga Luengo; Moises Labrador-Horrillo; Anna Sala-Cunill; Teresa Garriga
Journal:  Clin Transl Allergy       Date:  2011-10-17       Impact factor: 5.871

6.  Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.

Authors:  Andreas Körber; Charis Papavassilis; Vaishali Bhosekar; Maximilian Reinhardt
Journal:  Drugs Aging       Date:  2018-02       Impact factor: 3.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.